Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
Key Highlights
- ➤Start-up agreement launches planning for Niagen’s largest clinical trial to date
- ➤Proposed trial would test Niagen in adults aged 50 and older
- ➤MGB proposes randomized, placebo-controlled prevention trial spanning major aging outcomes
- ➤Final sample size, dose, duration, endpoints, and regulatory review remain undecided
- ➤Niagen Bioscience (NAGE) seeks additional organizations to support trial planning and execution
Expert Statements
Rob Fried, CEO of Niagen Bioscience
“This agreement reflects the next stage of responsible NAD+ science.”
Rob Fried, CEO of Niagen Bioscience
“As NAD+ continues to gain mainstream attention, a larger, longer, well-designed trial is needed to study the preventative, long term benefits of this remarkable ingredient, Niagen.”
Rob Fried, CEO of Niagen Bioscience
“The established products such as multivitamins, fish oil, and vitamin D have earned trust through large, long-term trials. We believe it is time for Niagen to earn similar status and adoption.”
Howard Sesso, Associate Director, Division of Preventive Medicine, Brigham and Women’s Hospital and Associate Professor of Medicine, Harvard Medical School
“Large-scale prevention trials are essential to understanding how nutrition interventions definitively impact clinically meaningful outcomes over time.”
Howard Sesso, Associate Director, Division of Preventive Medicine, Brigham and Women’s Hospital and Associate Professor of Medicine, Harvard Medical School
“Our unique hybrid randomized trial design will allow us to evaluate Niagen supplementation that combines clinical, functional, and wellness outcomes with novel biomarker measures and other innovative assessments relevant to aging biology and mechanisms of effect in subsets of participants.”
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
Proposed multi-year, randomized, placebo-controlled prevention trial would evaluate Niagen (patented nicotinamide riboside, or NR) supplementation across major clinical outcomes and healthy aging-related measures in adults aged 50 and older
Get started
Create a free account to read the full story.